Clinical trial · Observational
Precise Therapy for mCRPC Patients Through Whole Exome Sequencing(PTtWES)
Precise Therapy for mCRPC Patients Through Whole Exome Sequencing
NCT04126915CI-TRIAL-00041468PTtWESunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Through gene sequencing of the patient's tissue, to figure out the genomic characteristics of patients with advanced disease and guide the treatment of patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Castration-Resistant Prostatic Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Whole Exome Sequencing | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The genetic characteristics of mCRPC patients in China
- timeFrame
- June 2020
- description
- The genetic characteristics of mCRPC patients in China as Assessed by Gene Sequencing
Secondary outcomes (2)
- measure
- the possible prognostic therapeutic target
- timeFrame
- June 2023
- description
- the possible prognostic therapeutic target as Assessed by Gene Sequencing ，by observing the patient's prognosis，including PSA progression and progression in imaging by RECIST Version 1.1
- measure
- The best method to treat the disease
- timeFrame
- June 2023
- description
- Compare the effects of different treatments on the prognosis of patients as Assessed by PSA progression and progression in imaging by RECIST Version 1.1
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Expected survival period ≥ half a year; * Whole body bone scan (ECT) and magnetic resonance imaging (MRI) or PET-CT are evaluated as metastatic castration to resist prostate cancer patients; * Patients with evaluable and retrievable lesions; * Patients who voluntarily receive the experimental study protocol after informing the existing treatment plan; Exclusion Criteria: * Patients with other malignancies, or in acute infection or other severe infections; immunodeficiency virus (HIV), hepatitis C virus (HCV) and/or syphilis-positive patients; * Patients who have long-term anticoagulant and anti-platelet aggregation drugs (the anticoagulant is discontinued for less than 1 week); * At the same time suffering from other serious systemic diseases, the researchers believe that it may interfere with the treatment, evaluation and compliance of this test, including severe respiratory, circulatory, neurological, mental, digestive, endocrine, immune, urinary and other systems. disease; * The patient that it is inappropriate to participate in this clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.